Latest

Ozempic

·May 26, 2025·4 min read

Brainstem Neurons Hold Key to Semaglutide’s Weight Loss Effects

Researchers have identified a specific group of brainstem neurons that mediate the appetite-reducing and weight-loss effects of semaglutide without triggering side effects like nausea. In mice, activating these neurons led to reduced food intake and fat loss, mimicking the drug’s benefits.

Featured Neuroscience Psychology

·April 18, 2025·5 min read

Potential Depression Risk Linked to Ozempic-Like Drugs

A new international study reveals a possible connection between GLP1 receptor agonists—used in drugs like Ozempic—and increased risk of depression and suicidal ideation, especially in people with low dopamine function. Researchers used advanced pharmacogenomic tools to identify genetic pathways that may be vulnerable to dopamine dysregulation when exposed to these medications.

Featured Neurology Neuroscience

·April 16, 2025·5 min read

Ozempic Linked to Lower Alzheimer’s Risk

A new study suggests that two widely used Type 2 diabetes medications—GLP-1 receptor agonists and SGLT2 inhibitors—may help reduce the risk of Alzheimer’s disease and related dementias. Researchers analyzed Medicare data and found that patients taking these drugs had significantly lower rates of cognitive decline compared to those using other glucose-lowering medications.

Featured Neuroscience

·February 12, 2025·7 min read

Semaglutide Shows Promise in Reducing Alcohol Cravings and Consumption

A new study suggests that semaglutide, a drug commonly used for diabetes and obesity, may also help reduce alcohol consumption. Researchers found that weekly injections of semaglutide decreased alcohol cravings, drinking quantity, and heavy drinking days in adults with alcohol use disorder. Participants receiving semaglutide consumed less alcohol in a controlled lab setting and reported reduced cravings compared to those receiving a placebo.

This shows the outline of a person and a brain.

Featured Neuroscience

·January 20, 2025·6 min read

GLP-1 Drugs Offer Brain Benefits but May Pose Other Health Risks

A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like Ozempic and Wegovy, provide significant neurological and behavioral health benefits, including reduced risks of addiction, Alzheimer’s, and dementia. However, they also pose risks for pancreatitis and kidney conditions, emphasizing the need for careful monitoring.

Featured Neurology Neuroscience

·October 24, 2024·4 min read

Ozempic Shows Potential in Lowering Alzheimer’s Risk

New research suggests that semaglutide, a popular diabetes and weight-loss drug, may reduce the risk of Alzheimer’s disease in people with type 2 diabetes. The study compared semaglutide to seven other anti-diabetic drugs and found it was linked to a significantly lower risk of developing Alzheimer’s.

Featured Neuroscience Psychology

·September 4, 2024·5 min read

No Link Found Between Ozempic and Suicide Risk

A new study has found no evidence that GLP-1 analogues, common diabetes drugs, increase the risk of suicide, self-harm, or related mental health issues. Researchers analyzed data from around 300,000 people treated with these medications and found no clear link between the drugs and mental health risks.

Featured Genetics Neuroscience

·July 15, 2024·5 min read

Adjusting Proteins Increases Ozempic’s Effectiveness

Adjusting melanocortin proteins in the brain enhances the effectiveness of GLP-1 diabetes and weight-loss drugs. By inhibiting MC3R or activating MC4R, mice showed increased sensitivity to these drugs, leading to more significant weight loss and reduced feeding without additional side effects.

Featured Neurology Neuroscience

·July 12, 2024·5 min read

Ozempic Reduces Dementia Risk, Curbs Nicotine Cravings

A new study finds that semaglutide, known as Ozempic/Wegovy, does not negatively impact brain health and may reduce cognitive problems and nicotine dependence. The analysis, using over 100 million patient records, revealed no increased risk of neurological or psychiatric conditions compared to other antidiabetic medications. These findings suggest semaglutide's benefits may extend beyond diabetes management. Further research is needed to confirm these potential benefits.

Featured Neuroscience Visual Neuroscience

·July 3, 2024·7 min read

Ozempic Linked to Increased Risk of Blinding Eye Condition

A new study reveals that patients prescribed semaglutide (Ozempic or Wegovy) for diabetes or weight loss have a higher risk of developing NAION, a potentially blinding eye condition. Diabetic patients on semaglutide were over four times more likely to be diagnosed with NAION, while overweight patients were over seven times more likely. The findings suggest the need for careful discussions between patients and doctors about this risk. NAION remains a rare but serious condition with no effective treatments.

This shows an older man and a brain scan.

Featured Neurology Neuroscience

·June 21, 2024·4 min read

Ozempic May Reduce Alzheimer’s Risk

GLP-1 agonists like Ozempic reduce the risk of dementia in type 2 diabetes patients. The research followed over 88,000 individuals for up to ten years, showing a 30% lower risk compared to sulfonylureas and a 23% lower risk compared to DPP-4 inhibitors. These findings can guide doctors in selecting medications for older diabetes patients. However, further randomized trials are needed to confirm these results.

Featured Neuroscience Psychology

·June 3, 2024·3 min read

Ozempic May Reduce Alcohol Abuse Risk

Diabetes drugs Wegovy and Ozempic, containing semaglutide, significantly reduce the incidence and recurrence of alcohol-use disorder (AUD). Analyzing health records, researchers observed a 50% to 56% decrease in AUD among patients treated with semaglutide.

1 2

Ozempic

Brainstem Neurons Hold Key to Semaglutide’s Weight Loss Effects

Potential Depression Risk Linked to Ozempic-Like Drugs

Ozempic Linked to Lower Alzheimer’s Risk

Semaglutide Shows Promise in Reducing Alcohol Cravings and Consumption

GLP-1 Drugs Offer Brain Benefits but May Pose Other Health Risks

Ozempic Shows Potential in Lowering Alzheimer’s Risk

No Link Found Between Ozempic and Suicide Risk

Adjusting Proteins Increases Ozempic’s Effectiveness

Ozempic Reduces Dementia Risk, Curbs Nicotine Cravings

Ozempic Linked to Increased Risk of Blinding Eye Condition

Ozempic May Reduce Alzheimer’s Risk

Ozempic May Reduce Alcohol Abuse Risk

Music and Nature Work in Harmony to Ease Stress and Lift Mood

Listening to Music After 70 May Cut Dementia Risk by Nearly 40%

Brain Circuits Split Food Choices Between Sugar and Fat Cravings

Alzheimer’s Disrupts Brain’s Internal Clock, Unraveling Gene Rhythms

Subscribe